This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Amgen, Cytokinetics Report Mixed Results for Heart Failure Drug

Stocks in this article: AMGN CYTK

Seven patients treated with omecamtiv mecarbil suffered heart attacks during the study compared to three patients on placebo (2.3 percent vs. 1.3 percent.) Five of the drug-related heart attacks occurred in patients treated at the highest dose.

A further safety analysis showed no relationship between increasing blood levels of omecamtiv mecarbil and increases in troponin, a biomarker for heart-muscle damage. Still, the imbalance in heart attacks observed in the study has prompted Amgen and Cytokinetics to add heart attack as an identified risk for omecamtiv mecarbil, Amgen said.

Cytokinetics CEO Robert Blum, in an interview, said the 1.6 percent incidence of heart attack observed in the study overall was considered reasonably low by study investigators who met Monday in Amsterdam to discuss the study results.

The ATOMIC-AHF study is being presented Tuesday at the annual meeting of the European Society of Cardiology.

"We're impressed and pleased with the study results because the drug behaved consistent with what we've seen in previous studies," Blum said from Amsterdam.

Omecamtiv mecarbil is designed to increase the amount of time the heart is in its contraction phase, or pumping blood to the rest of the body, without causing significant side effects or increased risk of death. Currently approved drugs known as inotropes also boost cardiac output but are associated with an increased risk for heart arrhythmia and deaths.

Amgen and Cytokinetics are developing an intravenous and pill form of omecamtiv mecarbil. The idea is that patients hospitalized with an acute exacerbation of their heart failure could be stabilized quickly with an intravenous form of the drug, then given pills to take when they're sent home. Hospital re-admission of heart failure patients is a significant medical problem, so any drug that could keep patients stable and out of the hospital could see wide use.

More than 5 million people in the U.S. are diagnosed with heart failure and the cost to treat the disease totaled almost $40 billion in 2010, with much of the expense coming from hospitalizations.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,055.99 +2.28 0.01%
S&P 500 2,092.59 +3.82 0.18%
NASDAQ 4,810.4870 +3.6280 0.08%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs